Literature DB >> 1389943

Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects.

R Setiabudy, K Chiba, M Kusaka, T Ishizaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1389943      PMCID： PMC1381363     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

Review 1.  Genetic polymorphism of S-mephenytoin hydroxylation.

Authors:  G R Wilkinson; F P Guengerich; R A Branch
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

2.  Mephenytoin hydroxylation deficiency: kinetics after repeated doses.

Authors:  A Küpfer; P Desmond; R Patwardhan; S Schenker; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

3.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors:  Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

5.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

6.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

Authors:  P J Wedlund; W S Aslanian; E Jacqz; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030
  6 in total
  4 in total

1.  Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Wieling; D J Touw; R A de Zeeuw; L F de Leij; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

2.  Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Authors:  K Brøsen; E Skjelbo; H Flachs
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

3.  Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.

Authors:  Tobias Klaassen; Alexander Jetter; Dorota Tomalik-Scharte; Dirk Kasel; Julia Kirchheiner; Ulrich Jaehde; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-12-11       Impact factor: 2.953

4.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.